BioCentury
ARTICLE | Company News

Sarepta Therapeutics, University of Western Australia deal

April 15, 2013 7:00 AM UTC

The university granted Sarepta exclusive, worldwide rights to IP covering exon-skipping drug candidates for Duchenne muscular dystrophy (DMD). The university is eligible to receive up to $7.1 million in upfront and milestone payments, plus low single-digit royalties. The partners declined to disclose details. ...